TABLE 2.
COVID-19 CFRs from FAERS COVID-19 case reports, US only, overall and by treatment group, by vaccination coverage in the total population. Treatment groups are monotherapy only except for glucocorticoids, but within-group combinations (e.g., Ocrelizumab + Rituximab) are included. Cases with COVID-19 as only indication are excluded from the treatment group data sets. Data from 2020–01–22 to 2022–06–30, US. 95% confidence intervals (95%CI) from bootstrap resampling; CFRs that are significantly different from the baseline CFR are printed in bold (permutation test, Benjamini-Hochberg with an accepted FDR of 5% over all bins and treatment groups). Vaccination coverage bins, defined as (lower bound, upper bound], are by percentage of the total population who had received at least one dose, data from Our World in Data (Mathieu et al., 2020). Abbreviations: CFR: case fatality rate; COVID-19: Corona Virus Disease-2019; FAERS: FDA Adverse Event Reporting System.
| Vaccination coverage in total population | CFR (95% CI) from FAERS COVID-19 reports, US, 22 January 2020 to 30 June 2022, overall and by treatment group | ||||||
|---|---|---|---|---|---|---|---|
| Bin, % ≥ 1 dose | Covered period, both dates included | Whole dataset | Anti-CD20, monotherapy | Anti-TNFα, monotherapy | Glucocorticoids, incl. combinations | JAK inhibitors, monotherapy | Thalidomide analogs, monotherapy |
| baseline | 2020-01-22—2020-12–12 | 11.25 (10.63–11.89) | 13.07 (9.19–16.96) | 4.07 (2.62–5.52) | 19.19 (15.14–22.97) | 4.90 (3.50–6.41) | 17.08 (14.46–19.58) |
| 0–20 | 2020-12-13—2021-03–06 | 9.78 (9.11–10.44) | 6.55 (3.99–9.12) | 5.19 (3.4–6.98) | 11.83 (7.10–16.57) | 7.72 (5.57–9.87) | 11.62 (9.39–13.84) |
| 5–25 | 2021-01-18—2021-03–16 | 9.96 (9.14–10.81) | 7.04 (4.23–9.86) | 4.57 (2.54–6.6) | 12.77 (6.38–19.15) | 8.77 (6.03–11.78) | 11.11 (8.44–13.99) |
| 10–30 | 2021-02-04—2021-03–25 | 9.81 (8.87–10.77) | 5.60 (2.80–8.40) | 6.36 (3.18–9.55) | 19.23 (11.54–26.92) | 5.84 (3.11–8.67) | 11.21 (7.88–14.55) |
| 15–35 | 2021-02-23—2021-04–04 | 10.08 (8.93–11.26) | 7.53 (3.76–11.29) | 3.33 (0.67–6.67) | 21.33 (12.00–30.67) | 6.25 (2.84–10.23) | 12.56 (7.73–16.91) |
| 20–40 | 2021-03-07—2021-04–13 | 9.33 (8.14–10.53) | 6.17 (2.47–9.88) | 4.11 (1.37–7.53) | 21.74 (11.59–31.88) | 5.49 (2.20–8.79) | 11.25 (6.25–16.25) |
| 25–45 | 2021-03-17—2021-04–27 | 8.81 (7.66–10.01) | 7.64 (3.82–12.10) | 3.89 (1.11–6.67) | 25.00 (13.33–35.00) | 6.90 (3.45–10.92) | 13.92 (8.23–19.62) |
| 30–50 | 2021-03-26—2021-05–18 | 8.28 (7.23–9.33) | 10.62 (6.25–15.62) | 1.89 (0.38–3.79) | 29.09 (16.36–40.00) | 8.04 (4.52–12.06) | 13.12 (8.12–18.12) |
| 35–55 | 2021-04-05—2021-06–28 | 7.81 (6.98–8.70) | 8.11 (5.07–11.15) | 1.22 (0.3–2.43) | 22.47 (13.48–30.34) | 6.82 (3.64–10.45) | 12.62 (7.77–16.99) |
| 40–60 | 2021-04-14—2021-08–13 | 8.13 (7.33–8.91) | 8.68 (5.88–11.76) | 1.04 (0.26–2.07) | 17.88 (12.29–23.46) | 6.79 (3.77–9.81) | 13.41 (9.20–17.62) |
| 45–65 | 2021-04-28—2021-10–03 | 8.03 (7.42–8.67) | 7.76 (5.55–9.98) | 1.14 (0.33–1.95) | 17.09 (11.97–21.79) | 5.65 (3.53–7.76) | 11.87 (9.05–14.69) |
| 50–70 | 2021-05-19—2021-11–25 | 8.76 (8.18–9.34) | 13.25 (10.89–15.62) | 1.83 (0.84–2.81) | 15.58 (11.90–19.26) | 5.98 (4.04–7.91) | 11.90 (9.52–14.29) |
| 55–75 | 2021-06-29—2022-01–18 | 8.23 (7.72–8.74) | 14.73 (12.05–17.41) | 2.80 (1.6–4.0) | 16.00 (12.27–19.73) | 6.73 (4.82–8.63) | 8.96 (7.30–10.63) |
| >60 | 2021-08-14—2022-06–30 | 5.02 (4.74–5.30) | 13.40 (11.01–15.78) | 2.20 (1.49–2.98) | 17.99 (14.14–21.85) | 4.09 (3.22–5.03) | 6.15 (5.19–7.16) |
| >65 | 2021-10-04—2022-06–30 | 4.56 (4.28–4.84) | 16.09 (13.03–19.35) | 2.43 (1.53–3.33) | 18.46 (14.15–22.46) | 3.93 (2.99–4.92) | 5.35 (4.40–6.35) |
| >70 | 2021-11-26—2022-06–30 | 3.58 (3.31–3.84) | 6.91 (3.66–10.16) | 2.32 (1.33–3.32) | 19.34 (13.26–24.86) | 3.30 (2.38–4.30) | 4.33 (3.40–5.31) |
| >75 | 2022-01-19—2022-06–30 | 2.99 (2.72–3.26) | 5.85 (2.34–9.36) | 1.68 (0.78–2.59) | 21.74 (13.91–29.57) | 2.68 (1.79–3.66) | 4.28 (3.19–5.37) |